Edgestream Partners L.P. Has $5.19 Million Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

Edgestream Partners L.P. lifted its holdings in Blueprint Medicines Co. (NASDAQ:BPMC) by 443.7% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 56,123 shares of the biotechnology company’s stock after acquiring an additional 45,800 shares during the period. Edgestream Partners L.P.’s holdings in Blueprint Medicines were worth $5,191,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the business. Amalgamated Bank grew its stake in shares of Blueprint Medicines by 5.3% in the second quarter. Amalgamated Bank now owns 2,154 shares of the biotechnology company’s stock valued at $232,000 after acquiring an additional 109 shares in the last quarter. Van ECK Associates Corp grew its stake in Blueprint Medicines by 13.3% during the second quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock worth $120,000 after buying an additional 131 shares in the last quarter. EFG Asset Management North America Corp. grew its stake in Blueprint Medicines by 0.5% during the second quarter. EFG Asset Management North America Corp. now owns 27,884 shares of the biotechnology company’s stock worth $3,008,000 after buying an additional 132 shares in the last quarter. Pallas Capital Advisors LLC grew its stake in Blueprint Medicines by 3.2% during the third quarter. Pallas Capital Advisors LLC now owns 5,657 shares of the biotechnology company’s stock worth $523,000 after buying an additional 176 shares in the last quarter. Finally, Clarus Wealth Advisors grew its stake in Blueprint Medicines by 8.6% during the third quarter. Clarus Wealth Advisors now owns 2,590 shares of the biotechnology company’s stock worth $231,000 after buying an additional 206 shares in the last quarter.

Blueprint Medicines Stock Performance

Shares of BPMC stock opened at $96.38 on Friday. The company has a market cap of $6.12 billion, a price-to-earnings ratio of -45.68 and a beta of 0.59. Blueprint Medicines Co. has a 52 week low of $68.28 and a 52 week high of $121.90. The company has a quick ratio of 3.27, a current ratio of 3.32 and a debt-to-equity ratio of 1.09. The firm has a 50 day moving average of $90.97 and a 200-day moving average of $98.15.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, topping the consensus estimate of ($0.97) by $0.08. The company had revenue of $128.20 million during the quarter, compared to the consensus estimate of $127.56 million. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The company’s quarterly revenue was up 126.5% on a year-over-year basis. During the same quarter last year, the firm posted ($2.20) EPS. On average, equities analysts forecast that Blueprint Medicines Co. will post -3.68 earnings per share for the current year.

Analyst Ratings Changes

BPMC has been the topic of a number of analyst reports. HC Wainwright reiterated a “buy” rating and set a $135.00 price objective on shares of Blueprint Medicines in a research note on Friday, November 15th. JMP Securities reiterated a “market outperform” rating and set a $125.00 price objective on shares of Blueprint Medicines in a research note on Monday, November 18th. Wedbush reiterated an “outperform” rating and set a $135.00 price objective on shares of Blueprint Medicines in a research note on Thursday, November 14th. UBS Group initiated coverage on shares of Blueprint Medicines in a research note on Thursday, October 24th. They set a “neutral” rating and a $88.00 price objective on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and set a $135.00 price objective on shares of Blueprint Medicines in a research note on Friday, November 15th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $122.11.

Insider Activity at Blueprint Medicines

In related news, insider Fouad Namouni sold 3,633 shares of Blueprint Medicines stock in a transaction on Thursday, October 3rd. The shares were sold at an average price of $89.32, for a total value of $324,499.56. Following the completion of the sale, the insider now owns 69,070 shares of the company’s stock, valued at approximately $6,169,332.40. This trade represents a 5.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 4.21% of the stock is currently owned by insiders.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.